171 related articles for article (PubMed ID: 24915781)
1. Validation of the Fatigue Severity Scale in chronic hepatitis C.
Rosa K; Fu M; Gilles L; Cerri K; Peeters M; Bubb J; Scott J
Health Qual Life Outcomes; 2014 Jun; 12():90. PubMed ID: 24915781
[TBL] [Abstract][Full Text] [Related]
2. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.
Scott J; Rosa K; Fu M; Cerri K; Peeters M; Beumont M; Zeuzem S; Evon DM; Gilles L
BMC Infect Dis; 2014 Aug; 14():465. PubMed ID: 25164700
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
Zeuzem S; Berg T; Gane E; Ferenci P; Foster GR; Fried MW; Hezode C; Hirschfield GM; Jacobson I; Nikitin I; Pockros PJ; Poordad F; Scott J; Lenz O; Peeters M; Sekar V; De Smedt G; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Feb; 146(2):430-41.e6. PubMed ID: 24184810
[TBL] [Abstract][Full Text] [Related]
4. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies.
Scott J; Gilles L; Fu M; Brohan E; Panter C; Arbuckle R; Jessner W; Beumont M
J Viral Hepat; 2015 Aug; 22(8):639-50. PubMed ID: 25487355
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
7. Test-retest reliability, internal consistency and concurrent validity of Fatigue Severity Scale in measuring post-stroke fatigue.
Nadarajah M; Mazlan M; Abdul-Latif L; Goh HT
Eur J Phys Rehabil Med; 2017 Oct; 53(5):703-709. PubMed ID: 27768012
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia.
Gencay-Can A; Can SS
Rheumatol Int; 2012 Jan; 32(1):27-31. PubMed ID: 20658235
[TBL] [Abstract][Full Text] [Related]
9. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
[TBL] [Abstract][Full Text] [Related]
10. PSYCHOMETRIC PROPERTY OF FATIGUE SEVERITY SCALE AND CORRELATION WITH DEPRESSION AND QUALITY OF LIFE IN CIRRHOTICS.
Rossi D; Galant LH; Marroni CA
Arq Gastroenterol; 2017 Dec; 54(4):344-348. PubMed ID: 28977117
[TBL] [Abstract][Full Text] [Related]
11. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.
Kleinman L; Zodet MW; Hakim Z; Aledort J; Barker C; Chan K; Krupp L; Revicki D
Qual Life Res; 2000; 9(5):499-508. PubMed ID: 11190005
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
[TBL] [Abstract][Full Text] [Related]
14. Validity and reliability of fatigue severity scale in stroke.
Ozyemisci-Taskiran O; Batur EB; Yuksel S; Cengiz M; Karatas GK
Top Stroke Rehabil; 2019 Mar; 26(2):122-127. PubMed ID: 30475156
[TBL] [Abstract][Full Text] [Related]
15. Evaluating fatigue in patients recovering from COVID-19: validation of the fatigue severity scale and single item screening questions.
Naik H; Shao S; Tran KC; Wong AW; Russell JA; Khor E; Nacul L; McKay RJ; Carlsten C; Ryerson CJ; Levin A
Health Qual Life Outcomes; 2022 Dec; 20(1):170. PubMed ID: 36575437
[TBL] [Abstract][Full Text] [Related]
16. Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients.
Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
Brain Behav; 2017 Jul; 7(7):e00743. PubMed ID: 28729945
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale.
Learmonth YC; Dlugonski D; Pilutti LA; Sandroff BM; Klaren R; Motl RW
J Neurol Sci; 2013 Aug; 331(1-2):102-7. PubMed ID: 23791482
[TBL] [Abstract][Full Text] [Related]
20. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial.
Anderson RT; Baran RW; Erickson P; Revicki DA; Dietz B; Gooch K
Qual Life Res; 2014 Apr; 23(3):877-86. PubMed ID: 24036634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
